09.27.08

Study Quantifies Risk of Breast Cancer Recurrence

Posted in Uncategorized at 7:58 am by American Cancer Society :: News and Features

A Journal of the National Cancer Institute study offers women a detailed picture of the risk of recurrence years after treatment.

Study Adds Weight to Virtual Colonoscopy for Average-Risk Patients

Posted in Uncategorized at 7:58 am by American Cancer Society :: News and Features

Virtual colonoscopy is about as effective as traditional colonoscopy in finding colorectal cancer and large polyps, according to a new large study.

Lance Armstrong Announces Global Cancer Summit

Posted in Uncategorized at 7:58 am by American Cancer Society :: News and Features

Lance Armstrong has returned to cycling to take his "Live Strong" message worldwide.

Breast Cancer Patients Not Offered All Options For Reconstruction, UK

Posted in Uncategorized at 4:00 am by Breast Cancer News From Medical News Today

Free DVD for Breast Cancer Patients Revealing Range of Alternatives. An inequality in breast reconstruction options for mastectomy patients has been highlighted by a West Sussex hospital.

Breast MRI Scan Could Determine Need For Radiation Therapy

Posted in Uncategorized at 1:00 am by Breast Cancer News From Medical News Today

For women whose breast cancer has spread to their lymph nodes, a magnetic resonance imaging (MRI) scan could replace exploratory surgery as the method for determining whether those women need radiation therapy to treat their disease, according to a study to be presented during the annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) which opens in Boston.

New Computer Based Tools Will Help Make Best Use Of Genetic Breast Cancer Tests

Posted in Uncategorized at 1:00 am by Breast Cancer News From Medical News Today

A new federal project, funded by the Agency for Healthcare Research and Quality, will lead efforts to develop, implement and evaluate four computer-based decision-support tools that will help clinicians and patients better use genetic tests to evaluate and treat breast cancer. The first pair of tools will assess whether a woman with a family history of cancer should be tested for BRCA1 and BRCA2 gene mutations.

09.26.08

Breast, Ovarian Cancer Prediction Models More Accurate For White Women Than Asian-American Women, Study Finds

Posted in Uncategorized at 8:00 am by Breast Cancer News From Medical News Today

Two widely used prediction models for identifying a woman's risk for breast and ovarian cancer appear to be less reliable for Asian-American women compared with white women, according to a study in the October issue of the Journal of Clinical Oncology, Reuters Health reports. For the study, lead researcher Allison Kurian of

Randomized Phase 2 Study Of IMC-A12 For Advanced Breast Cancer Commences Patient Enrollment

Posted in Uncategorized at 7:00 am by Breast Cancer News From Medical News Today

ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that its disease-directed randomized Phase 2 clinical trial of IMC-A12, ImClone's fully human, IgG1 anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody, in women with advanced breast cancer has commenced patient enrollment.

Deactivating A Cancer Growth Promoter

Posted in Uncategorized at 5:00 am by Breast Cancer News From Medical News Today

Three enzymes called phosphatases that shut down a molecule called SRC-3 (steroid receptor coactivator 3) could provide a new pathway for fighting cancer, particularly tumors of the breast and prostate, said researchers at Baylor College of Medicine in a report that appears in the current issue of the journal Molecular Cell. "This kind of information provides a target for the production of drugs against cancer," said Dr.

Concert Pharmaceuticals Presents Preclinical Results Supporting Co-Administration Of CTP-347 And Tamoxifen

Posted in Uncategorized at 3:00 am by Breast Cancer News From Medical News Today

Concert Pharmaceuticals, Inc. announced today the presentation of data from a preclinical study demonstrating the potential of CTP-347, its novel deuterium-containing serotonin modulator, to avoid the risk of adverse drug-drug interactions when co-administered with tamoxifen, a widely-used breast cancer drug. These data were the subject of a poster presentation at the North American Menopause Society's 2008 Annual Meeting.

« Previous entries · Next entries »